NON-SMALL CELL LUNG CANCER

This study tested a drug called durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two other treatments, including chemotherapy. The goal was to see if the drug could shrink tumors and how safe it was. Participants received the drug e…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including a type of lung cancer. The drug works by activating the body's immune T-cells to fight cancer. The main goals were to check safety, find the best dose, and see how the d…

This study tested whether giving palliative radiotherapy to 2-5 metastatic sites before starting first-line immunotherapy and chemotherapy can improve outcomes for people with advanced non-small cell lung cancer. 50 participants with PD-L1 below 50% received this combined approac…

This study tested a combination of two drugs, pembrolizumab and Imprime PGG, in 35 adults with advanced non-small cell lung cancer that had worsened after first-line therapy. The goal was to find the best dose and see if the combination could slow cancer growth. The study was com…

This study tested whether adding lenvatinib to the immunotherapy drug pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. Over 600 adults with tumors showing at least 1% PD-L1 took part. The main goals were to see if the c…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The goal was to see if the combinatio…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 participants took part. The goal was to see how many patients had their tumors…

This study tested a new way of giving radiation therapy (hybrid dose-fraction radiotherapy) along with immunotherapy for people with advanced non-small cell lung cancer that has spread. The goal was to see if this combination is safe and can help control the cancer longer. 78 adu…

This study looked at the safety of the drug sotorasib in 102 Chinese adults with a specific type of advanced lung cancer (KRAS G12C-mutated NSCLC) who had already tried other treatments. Researchers tracked side effects like liver problems, lung inflammation, and kidney issues. T…

This early-phase study tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several advanced cancers, including melanoma, lung cancer, and others. The goal was to see if blocking a signal that protects cancer cells could help the immune sys…

This study tested whether the immunotherapy drug pembrolizumab could help prevent non-small cell lung cancer from coming back after surgery. About 1,177 people with stage IB to IIIA lung cancer who had their tumor removed received either pembrolizumab or a placebo. The main goal …

This study looked at whether switching from the immunotherapy durvalumab to the targeted pill sotorasib could better control locally advanced non-small cell lung cancer in people with a KRAS G12C mutation. The switch was triggered when a blood test showed signs of remaining cance…

This early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 adults with advanced or metastatic solid tumors, including lung cancer. The goal was to find safe doses for future larger studies. The tr…

This early-phase study tested a new treatment for people with advanced non-small cell lung cancer that had grown or returned after standard therapy. Researchers took participants' own immune cells, modified them in a lab to better recognize and attack cancer, and infused them bac…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested whether adding the immunotherapy drug serplulimab to standard chemotherapy before and after surgery helps people with stage II-IIIA non-small cell lung cancer. 30 patients received the combination treatment. The main goal was to see how many had a major response…

This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers that had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can reduce canc…

This study tested giving the immunotherapy drug tislelizumab, alone or with other treatments, before surgery for stage II to IIIA non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. 121 adults with operable lung cancer too…

This early-phase study tested the drug RAD001 (everolimus) combined with radiation therapy in 26 people with advanced non-small cell lung cancer that could not be removed by surgery. The main goal was to find the safest dose and identify side effects. Participants took RAD001 wee…

This early-phase study tested a new drug called TPST-1495, alone or with another drug (pembrolizumab), in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest…

This study looked at 156 adults with advanced non-small cell lung cancer whose first chemotherapy stopped working. It compared taking two drugs (erlotinib pills followed by docetaxel infusion) versus docetaxel alone. The goal was to see if the combo could delay cancer growth long…

This study tested a combination of two drugs, RMC-4630 and sotorasib, in 47 adults with advanced non-small cell lung cancer that has a specific KRASG12C mutation and has stopped responding to standard treatments. The goal was to see if the combination could shrink tumors. Partici…

This early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…

This study tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a certain type of advanced lung cancer (non-small cell lung cancer that is PD-L1 positive). The trial involved 118 adults who had not received prior treatment for the…

This study tested a new drug called gimistotug (BGB-A445) combined with other investigational drugs in 35 people with advanced non-small cell lung cancer who had already received standard treatments. The main goal was to see if the combination could shrink tumors. The trial is no…

This study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous non-small cell lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could slow down cancer growth. Th…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, …

This study tested a combination of two drugs, NT-I7 and pembrolizumab, in 215 people with advanced solid tumors that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combo could shrink tumors. The study included people with several…

This study tested whether adding tiragolumab to atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer who had not received prior treatment. 135 participants were randomly assigned to receive either the combination or a placebo plus …

This study tested whether a short course of radiation to one tumor site could make immunotherapy work better in people with advanced lung or head/neck cancer. 76 participants received radiation within two weeks of starting their first immunotherapy dose. The main goal was to see …

This study tested a combination of two drugs, nivolumab and ALT-803, in 67 patients with advanced non-small cell lung cancer that had already been treated. The goal was to find a safe dose and see how many patients' tumors shrank. The approach aims to boost the immune system to f…

This study tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combo could delay cancer growth and to check…

This study tested whether a shot (subcutaneous) form of the immunotherapy drug atezolizumab works as well as the standard IV version for people with advanced non-small cell lung cancer. About 438 patients who had already tried platinum-based chemotherapy took part. The goal was t…

This early-phase study tested the safety of a new drug called GDC-1971 when given with either osimertinib (for lung cancer) or cetuximab (for colorectal cancer). It involved 10 adults with advanced cancer that had spread or couldn't be removed. The main goal was to check for side…

This study tested whether giving lung cancer treatments based on the genetic makeup of a person's tumor could improve outcomes. About 50 adults with non-small cell lung cancer that came back after initial treatment received either immunotherapy (atezolizumab) or targeted drugs li…

This study tested a new drug, BA3011, alone or with an immunotherapy (PD-1 inhibitor) in 85 adults with advanced non-small cell lung cancer that had stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check for side effects. The stud…

This study tested a new drug called AZD3759 against standard targeted therapies (gefitinib or erlotinib) in 492 adults with advanced lung cancer that has a specific gene mutation (EGFR) and has spread to the brain. The goal was to see if AZD3759 could better delay cancer growth. …

This early-phase trial tested whether injecting the chemotherapy drug cisplatin directly into lung tumors during a bronchoscopy is safe for people with early-stage, resectable non-small cell lung cancer. Six participants were enrolled to find the highest safe dose. The goal was t…

This study tested a drug called trastuzumab deruxtecan in 152 people with a specific type of advanced lung cancer (HER2-mutated) that had gotten worse after standard treatment. The main goal was to see if the drug could shrink tumors. The study was completed and measured how many…

This study tested whether adding tiragolumab to atezolizumab helps people with advanced non-small cell lung cancer that hasn't been treated yet. About 620 participants received either the combination or a placebo plus atezolizumab. The goal was to see if the new combo slows cance…

This study tested a new drug called AK112 in 108 adults with advanced non-small cell lung cancer (stage IIIB/IV) whose tumors had a PD-L1 score of 1% or higher. The drug is a bispecific antibody that targets both PD-1 and VEGF to help the immune system fight cancer and slow tumor…

This study looked at whether a targeted treatment called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows rising levels of cancer DNA (minimal residual disease or MRD). 37 participants received LAT to all visible …

This study tested whether adding an experimental drug called custirsen to the standard chemo docetaxel helps people with advanced non-small cell lung cancer live longer. About 664 adults who had already tried one prior treatment took part. The goal was to compare overall survival…

This study tested adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these combinations could improve outcomes like preventing cancer from coming …

This early-phase study tested whether adding copanlisib to the immunotherapy durvalumab is safe and can help overcome resistance in people with stage III non-small cell lung cancer that cannot be removed by surgery. Eleven participants who had already received chemotherapy and ra…

This early-phase study tested a new drug called CHS-388 in 145 people with advanced solid tumors (including kidney, liver, and lung cancers) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cance…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic markers. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment tailored to their cancer's genetic…

This early-phase study tested a personalized vaccine made from yeast that is designed to teach the immune system to recognize and attack leftover cancer cells. It included 5 adults with different cancers who had already completed treatment aimed at curing their disease. The goal …

This early-phase study tested a new daily pill called JAB-3312 in 40 adults with advanced solid tumors (like lung, colorectal, or breast cancer) that had stopped responding to standard treatments. The main goals were to find the safest dose and check for side effects. Researchers…

This early-phase study tested a new drug (BGB-A445) alone and with another drug (tislelizumab) in 204 people with advanced solid tumors like lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. This is not a cure, but aims t…

This study tested whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. About 789 participants received either the combination or chemotherapy alone. The goal was to see if the combo improves s…

This study tested a drug called AZD9291 in 171 adults from Asia Pacific with advanced non-small cell lung cancer that had a specific gene mutation (T790M). All participants had already tried other treatments that stopped working. The goal was to see if the drug could shrink tumor…

This study looked at how safe and effective Tabrecta is for people with a certain type of advanced lung cancer (MET exon 14 skipping mutation). 109 patients were followed for up to a year. The goal was to track side effects and see how well the drug controlled the cancer.

This study tested a combination of two targeted drugs, encorafenib and binimetinib, in 98 people with a specific type of advanced lung cancer (BRAFV600-mutant non-small cell lung cancer). The goal was to see if the drugs could shrink tumors. Participants had either not received p…

This study tested whether customizing chemotherapy based on two genetic markers (EGFR mutations and BRCA1 levels) improves outcomes for people with advanced lung adenocarcinoma. 153 patients received treatments matched to their tumor's genetic profile. The goal was to see if this…

This study tested a new drug called ensartinib (X-396) in 131 people with advanced solid tumors, including a type of lung cancer driven by an ALK gene change. The main goals were to find the safest dose and see if the drug could shrink tumors. Early results suggest it may help co…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer without their cancer growing. About 2,700 patients who had not received prior t…

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy helps people with advanced central non-small cell lung cancer. The trial included 33 adults whose cancer could not be surgically removed. The goal was to see if the triple …

This study tested a combination of two drugs (ningetinib and gefitinib) in 108 people with advanced non-small cell lung cancer whose tumors had a specific gene change (EGFR mutation) but not another (T790M), and whose cancer had stopped responding to standard targeted therapy. Th…

This study tested a personalized approach to radiation therapy for people with stage III lung cancer that cannot be removed by surgery. During standard chemo-radiation, doctors used PET scans to see how the tumor was responding and adjusted the radiation dose to target stubborn a…

This study tested a daily pill called sotorasib in 42 adults with advanced lung cancer that has a specific genetic change (KRAS G12C) and has not been treated yet. The goal was to see if the drug shrinks tumors and how safe it is. Participants received either a 960 mg or 240 mg d…

This early-phase trial tested whether adding the drug pirfenidone to standard chemotherapy is safe and effective for people with advanced non-small cell lung cancer. 48 participants received the combination to find the best dose and see if tumors shrank. The goal was to control t…

This study looked at whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) after standard chemoradiation can help people with stage III lung cancer that cannot be removed by surgery. About 105 participants were enrolled. The goal was to see if these treatments c…

This study tested a new drug called DS-1062a in 137 adults with advanced or spreading non-small cell lung cancer that has certain gene changes. Participants had already tried targeted therapy and platinum chemotherapy without success. The main goal was to see if the drug could sh…

This early-stage study tested whether adding PB101 (a patient's own immune cells) to standard targeted therapy (EGFR-TKI) is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was …

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested a blood test that looks for cancer DNA in the blood of 22 people with advanced lung cancer. The goal was to see if the blood test works as well as the standard tissue biopsy to find genetic changes in the tumor. If successful, this could make testing easier and …

This study tested whether a new blood test (liquid biopsy) can accurately find cancer biomarkers in patients with head and neck, lung, or skin cancer. 135 adults with advanced cancer provided blood and tumor tissue samples. The goal was to see if the blood test works as well as t…

This study tested a new bendable surgical tool (SurgeoFlex Grasp) against a standard rigid tool in 100 adults with early-stage lung cancer undergoing keyhole surgery. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument clashes, and eases s…

This study looked at whether a special supplement with essential amino acids could help people with advanced lung cancer build more protein in their bodies. Many lung cancer patients lose weight and muscle, which makes them feel worse and can affect treatment. The researchers gav…

This study tested a low-cost, portable exercise program to help people with non-small cell lung cancer manage severe tiredness after surgery. 235 adults took part. The program aimed to reduce fatigue and improve quality of life by teaching patients how to self-manage their energy…

This study looked at whether adding structured family support to standard palliative care helps people with advanced lung cancer feel better and make clearer decisions. 110 adults were split into two groups: one received routine care, the other added family involvement, counselin…

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week course, while the other had a shorter 4-week course based on PET scans. The main goal was to see how patients felt during and after t…

This study tested a faster radiation treatment called Quad Shot for people with advanced lung cancer who are also receiving other cancer drugs. The goal was to see if giving radiation in fewer, more intense sessions is safe and less likely to interfere with their regular treatmen…

This study tested whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a quick shot under the skin (subcutaneous) or as a longer IV drip into a vein. About 179 patients tried both methods and reported which they liked better. The goal was to see …

This study reviewed medical records of 350 Australian adults with advanced EGFR-mutant non-small cell lung cancer to see how they were treated with the drug osimertinib and what happened over time. Researchers looked at how long patients stayed on treatment, how long they lived, …

This study looked at whether a test using 6 different markers from tumor samples could predict if advanced lung cancer patients would live longer or have their cancer worsen after treatment with immunotherapy plus chemotherapy. Researchers studied 106 patients and compared the te…

This study looked at how the lung cancer drug AZD9291 (osimertinib) changes the way the body processes simvastatin, a common cholesterol medicine. It involved 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive) whose disease had worsened after previous…

This study looked at medical records of 833 people with advanced non-small cell lung cancer to understand what treatments they received and how they fared. Researchers gathered data from doctors' surveys across multiple countries. The goal was to learn about real-world care patte…

This study looked at the nutrition and body composition of 25 people with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and diet, and checked for muscle loss and weakness. The goal was to understand how nutrition relate…

This study looked at whether people with advanced cancer (melanoma, kidney, or lung cancer) who are starting immunotherapy can collect tiny blood samples at home using a finger-prick method. The goal was to see if this approach is practical and if the samples are good enough for …

This study looked back at the medical records of 60 people with advanced lung cancer to see if taking a common heart medication (beta-blockers) alongside immunotherapy affected their treatment results. Researchers compared how long the cancer was controlled and survival rates bet…

This study looked at 70 people with advanced lung cancer whose tumors had a specific gene change (EGFR mutation) and had stopped responding to initial targeted therapy. Researchers used a simple blood test (liquid biopsy) to check for a new resistance mutation (T790M) that can gu…

This study analyzed lung cancer tissue from 56 patients to look for pieces of a protein called Met. Researchers compared tumor samples with healthy tissue to see which fragments were present and whether they were active. The goal was to better understand the disease, not to test …

This study looked at 40 adults with non-small cell lung cancer who had chemoradiation. Researchers compared a special type of PET scan (parametric imaging) to standard PET scans to see which better predicts if the cancer will come back within a year. The goal was to find a more a…

This study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted therapies. Instead of a tissue biopsy, researchers used a simple blood test (liquid biopsy) to find genetic changes that cause drug resistance. The goal was to bette…

This study explored whether emotional distress before treatment and certain blood markers (like inflammation levels) can predict how well immunotherapy works in people with advanced lung or stomach cancer. Researchers followed 196 patients who had not received prior treatment. Th…

This study looked at 212 adults with advanced non-small cell lung cancer who received the immunotherapy drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug …

This study looked at how a new cancer drug called MK-1084 changes the way the body processes two other drugs, midazolam and digoxin. 28 healthy adults took part to help researchers understand if MK-1084 affects the levels of these medicines. The goal was to gather safety and dosi…

This study looked at medical records of nearly 5,000 people with non-small cell lung cancer to see if they could get the same results as a famous clinical trial (FLAURA). The goal was not to test a new treatment, but to learn when and how real-world data can be trusted for resear…

This study reviewed medical records of 240 adults in Poland with advanced non-small cell lung cancer who received a combination of two immunotherapy drugs plus chemotherapy as their first treatment. The goal was to see how well the treatment worked in everyday hospital care, not …

This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) that had stopped responding to targeted treatments. The goal was to find genetic changes in the blood that explain why the drugs stopped working. By matching these changes to the …

This study looked at 40 people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. They received the immunotherapy drug pembrolizumab, and researchers used PET scans after the first dose to see if early changes in tumor activity could predict whether the…

This study monitored 1,290 patients with non-small cell lung cancer who were already taking the drug Lorbrena after it was approved. The goal was to track side effects, especially brain and liver problems. No new treatment was given; it was purely an observation of real-world saf…

This study tested a special breathing-synchronized PET scan method to get clearer images of small lung nodules. 103 adults with lung nodules (from cancer or COPD) had a standard PET scan plus an extra 10-minute gated scan. The goal was to see if the new method reduces motion blur…

This study looked at whether adding a simple blood test (liquid biopsy) to the standard tissue test could help find more gene changes (EGFR mutations) in people with advanced lung cancer. Over 500 patients who had not yet been treated provided both blood and tissue samples. The g…

This study aimed to find biological markers in the blood and tumors that could predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug atezolizumab. Researchers analyzed immune cells, genetics, and microbiomes from 100 participants. Th…

This study created a regional database of 518 adults with non-small cell lung cancer who had a gene mutation. Researchers collected detailed clinical information, such as age, smoking history, and cancer stage, to see how these factors relate to different mutations. The goal was …